aTyr Pharma (ATYR) Stock Price

aTyr Pharma Price

NASDAQ·CLOSED
0.53USD+0.01 (+2.53 %)
Market closed

Revenue at aTyr Pharma has contracted by 12.5% per year over the past 6 years to 190,000.00 USD. aTyr Pharma's net margin stands at -39,009.5%, down from -155.2% several years earlier. Analysts set a median price target of 1.02 USD, implying 91.9% above the current price. Of 16 analysts, 8 rate the stock a buy — an overall Buy consensus. Over the past year aTyr Pharma shares have gained 14.3%. The stock trades about 46% above its 52-week low.

aTyr Pharma stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of aTyr Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how aTyr Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing aTyr Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

aTyr Pharma Stock Price History
DateaTyr Pharma Price
8/19/20260.53 USD
8/18/20260.52 USD
8/17/20260.52 USD
8/14/20260.56 USD
8/13/20260.55 USD
8/12/20260.55 USD
8/10/20260.53 USD
8/7/20260.51 USD
8/6/20260.50 USD
8/5/20260.52 USD
8/4/20260.53 USD
8/3/20260.49 USD
7/31/20260.49 USD
7/30/20260.48 USD
7/29/20260.48 USD
7/27/20260.49 USD
7/23/20260.50 USD
7/22/20260.49 USD
7/21/20260.49 USD
7/20/20260.49 USD
7/17/20260.51 USD
7/16/20260.52 USD
7/15/20260.53 USD
7/14/20260.49 USD
7/13/20260.51 USD
7/10/20260.54 USD
7/9/20260.58 USD
7/8/20260.61 USD
7/7/20260.61 USD
7/6/20260.62 USD
7/2/20260.59 USD
7/1/20260.59 USD
6/30/20260.60 USD
6/29/20260.57 USD
6/26/20260.53 USD
6/25/20260.56 USD
6/24/20260.56 USD
6/23/20260.54 USD
6/22/20260.47 USD
6/18/20260.45 USD
6/17/20260.46 USD
6/16/20260.45 USD
6/15/20260.44 USD
6/12/20260.44 USD
6/11/20260.47 USD
6/10/20260.47 USD
6/9/20260.46 USD
6/8/20260.44 USD
6/5/20260.47 USD
6/4/20260.51 USD
6/3/20260.50 USD
6/2/20260.52 USD
6/1/20260.55 USD
5/29/20260.54 USD
5/28/20260.49 USD
5/27/20260.48 USD
5/26/20260.48 USD
5/22/20260.49 USD
5/21/20260.53 USD
5/20/20260.53 USD
5/19/20260.48 USD
5/18/20260.52 USD
5/15/20260.50 USD
5/14/20260.56 USD
5/13/20260.40 USD
5/12/20260.53 USD
5/11/20260.53 USD
5/8/20260.53 USD
5/7/20260.51 USD
5/6/20260.58 USD
5/5/20260.47 USD
5/4/20260.47 USD
5/1/20260.47 USD
4/30/20260.45 USD
4/29/20260.43 USD
4/28/20260.44 USD
4/27/20260.44 USD
4/24/20260.44 USD
4/23/20260.44 USD
4/22/20260.47 USD
4/21/20260.46 USD
4/20/20260.48 USD
4/17/20260.48 USD
4/16/20260.46 USD
4/15/20260.47 USD
4/14/20260.47 USD
4/13/20260.45 USD
4/10/20260.46 USD
4/9/20260.42 USD
4/8/20260.45 USD
4/7/20260.44 USD
4/6/20260.46 USD
4/2/20260.47 USD
4/1/20260.47 USD
3/31/20260.44 USD
3/30/20260.41 USD
3/27/20260.42 USD
3/26/20260.44 USD
3/25/20260.45 USD
3/24/20260.44 USD
3/23/20260.46 USD
3/20/20260.45 USD
3/19/20260.46 USD
3/18/20260.45 USD
3/17/20260.49 USD
3/16/20260.50 USD
3/13/20260.47 USD
3/12/20260.48 USD
3/11/20260.51 USD
3/10/20260.52 USD
3/9/20260.50 USD
3/6/20260.46 USD
3/5/20260.50 USD
3/4/20260.54 USD
3/3/20260.54 USD
3/2/20260.55 USD
2/27/20260.54 USD
2/26/20260.55 USD
2/25/20260.57 USD
2/24/20260.55 USD
2/23/20260.56 USD
2/20/20260.58 USD
2/19/20260.59 USD
2/18/20260.55 USD
2/17/20260.55 USD
2/13/20260.50 USD
2/12/20260.50 USD
2/11/20260.52 USD
2/10/20260.49 USD
2/9/20260.50 USD
2/6/20260.50 USD
2/5/20260.45 USD
2/4/20260.49 USD
2/3/20260.54 USD
2/2/20260.54 USD
1/30/20260.49 USD
1/29/20260.47 USD
1/28/20260.38 USD
1/27/20260.39 USD
1/26/20260.39 USD
1/23/20260.40 USD
1/22/20260.42 USD
1/21/20260.40 USD
1/20/20260.39 USD
1/16/20260.40 USD
1/15/20260.39 USD
1/14/20260.40 USD
1/13/20260.39 USD
1/12/20260.38 USD
1/9/20260.40 USD
1/8/20260.40 USD
1/7/20260.42 USD
1/6/20260.40 USD
1/5/20260.42 USD
1/2/20260.42 USD
12/31/20250.44 USD
12/30/20250.42 USD
12/29/20250.42 USD
12/26/20250.41 USD
12/24/20250.41 USD
12/23/20250.40 USD
12/22/20250.41 USD
12/19/20250.42 USD
12/18/20250.39 USD
12/17/20250.40 USD
12/16/20250.41 USD
12/15/20250.41 USD
12/12/20250.43 USD
12/11/20250.43 USD
12/10/20250.46 USD
12/9/20250.45 USD
12/8/20250.45 USD
12/5/20250.46 USD
12/4/20250.46 USD
12/3/20250.43 USD
12/2/20250.39 USD
12/1/20250.41 USD
11/28/20250.44 USD
11/26/20250.43 USD
11/25/20250.43 USD
11/24/20250.43 USD
11/21/20250.37 USD
11/20/20250.36 USD
11/19/20250.38 USD
11/18/20250.39 USD
11/17/20250.38 USD
11/14/20250.42 USD
11/13/20250.40 USD
11/12/20250.40 USD
11/11/20250.44 USD
11/10/20250.44 USD
11/7/20250.46 USD
11/6/20250.43 USD
11/5/20250.45 USD
11/4/20250.46 USD
11/3/20250.49 USD
10/31/20250.48 USD
10/30/20250.50 USD
10/29/20250.54 USD
10/28/20250.54 USD
10/27/20250.54 USD
10/24/20250.54 USD
10/23/20250.54 USD
10/22/20250.54 USD
10/21/20250.57 USD
10/20/20250.57 USD
10/17/20250.57 USD
10/16/20250.56 USD
10/15/20250.57 USD
10/14/20250.58 USD
10/13/20250.54 USD
10/10/20250.59 USD
10/9/20250.53 USD
10/8/20250.56 USD
10/7/20250.47 USD
10/6/20250.46 USD
10/3/20250.43 USD
10/2/20250.40 USD
10/1/20250.38 USD
9/30/20250.40 USD
9/29/20250.44 USD
9/26/20250.47 USD
9/25/20250.50 USD
9/24/20250.53 USD
9/23/20250.55 USD
9/22/20250.59 USD
9/19/20250.55 USD
9/18/20250.59 USD
9/17/20250.57 USD
9/16/20250.60 USD
9/15/20250.57 USD
9/12/20250.57 USD
9/11/20250.49 USD
9/10/20250.49 USD
9/9/20250.50 USD
9/8/20250.51 USD
9/5/20250.53 USD
9/4/20250.51 USD
9/3/20250.54 USD
9/2/20250.53 USD
8/29/20250.51 USD
8/28/20250.50 USD
8/27/20250.49 USD
8/26/20250.48 USD
8/25/20250.48 USD
8/22/20250.50 USD
8/21/20250.46 USD
Access this data via the Eulerpool API
Get Free API Key

aTyr Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
353,000.00 USD
-54.92 M USD
-50.39 M USD
Jan 1, 2024
235,000.00 USD
-67.91 M USD
-64.02 M USD
Jan 1, 2025
190,000.00 USD
-77.63 M USD
-74.12 M USD
Jan 1, 2026 (e)
0.00 USD
-76.06 M USD
-55.25 M USD
Jan 1, 2027 (e)
0.00 USD
-64.56 M USD
-59.99 M USD
Jan 1, 2028 (e)
291.08 M USD
-56.10 M USD
114.81 M USD
Jan 1, 2029 (e)
550.43 M USD
55.70 M USD
283.69 M USD
Jan 1, 2030 (e)
805.00 M USD
210.29 M USD
426.96 M USD

aTyr Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 2:09 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
–––––10.00–10.00–––––291.00550.00805.00
––––––––––––––89.0046.36
–––––-60.00–80.00–––––-0.34-0.18-0.12
-1.00-1.00-1.00-1.00-13.00-6.00-1.008.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00
-47.00-59.00-47.00-32.00-22.00-15.00-34.00-46.00-54.00-67.00-77.00-76.00-64.00-56.0055.00210.00
–––––-150.00–-460.00–––––-19.2410.0026.09
-47.00-57.00-48.00-34.00-23.00-16.00-33.00-45.00-50.00-64.00-74.00-55.00-59.00114.00283.00426.00
95.8321.28-15.79-29.17-32.35-30.43106.2536.3611.1128.0015.63-25.687.27-293.22148.2550.53
1.691.692.132.173.8910.5727.7929.1259.2682.7298.0198.0198.0198.0198.0198.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales aTyr Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue aTyr Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare aTyr Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares aTyr Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against aTyr Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

aTyr Pharma stock margins

The aTyr Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of aTyr Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for aTyr Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-717.37 %
- %
- %
Jan 1, 2022
83.68 %
-446.79 %
-436.53 %
Jan 1, 2023
100.00 %
-15,557.79 %
-14,274.50 %
Jan 1, 2024
100.00 %
-28,899.58 %
-27,243.83 %
Jan 1, 2025
-717.37 %
-40,856.32 %
-39,009.47 %
Jan 1, 2026 (e)
-717.37 %
- %
- %
Jan 1, 2027 (e)
-717.37 %
- %
- %
Jan 1, 2028 (e)
-717.37 %
-19.27 %
39.44 %

aTyr Pharma Stock Revenue, EBIT, Earnings per Share

The aTyr Pharma earnings per share therefore indicates how much revenue aTyr Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-1.22 USD
-1.22 USD
Jan 1, 2022
0.36 USD
-1.59 USD
-1.56 USD
Jan 1, 2023
0.01 USD
-0.93 USD
-0.85 USD
Jan 1, 2024
0.00 USD
-0.82 USD
-0.77 USD
Jan 1, 2025
0.00 USD
-0.79 USD
-0.76 USD
Jan 1, 2026 (e)
0.00 USD
-0.78 USD
-0.56 USD
Jan 1, 2027 (e)
0.00 USD
-0.66 USD
-0.61 USD
Jan 1, 2028 (e)
2.97 USD
-0.57 USD
1.17 USD

aTyr Pharma business model & stock analysis

aTyr Pharma Inc is a biotechnology company based in San Diego, California. Founded in 2005, the company has gained a lot of attention in recent years for its focus on developing drugs based on proteomics, the analysis of proteins. The idea for aTyr came from the realization that there are a variety of proteins that can be used as a basis for developing new drugs. The company has developed a unique proteomics platform that allows for the identification and utilization of previously undiscovered proteins to understand biological processes and develop new drugs for diseases. aTyr specializes in the discovery and development of proteins associated with rare but difficult-to-treat diseases. This includes rare muscle diseases and lung diseases. The company collaborates closely with clinicians and scientists to advance its research and development. aTyr's business model is based on the development of new drugs based on proteomics, with a focus on rare diseases that are often neglected. The goal is to improve the quality of life for patients by developing new and innovative drugs. aTyr has various divisions, including therapeutic proteins and diagnostics. The company has a number of drugs in development targeting different diseases. This includes Resolaris, a protein focused on rare muscle diseases, and ATYR1923, developed for the treatment of lung diseases. Resolaris is a novel protein targeting rare muscle diseases such as FSHD and LGMD. It is currently being tested in clinical trials and has the potential to significantly improve the quality of life for patients with these severe conditions. The company is also developing ATYR1923, a protein for the treatment of lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Overall, aTyr Pharma is an innovative company focused on the development of novel drugs based on proteomics. With its unique proteomics platform, the company has the potential to identify and utilize previously undiscovered proteins to understand biological processes and develop new drugs for diseases. With its various divisions, including therapeutic proteins and diagnostics, the company has the potential to improve the treatment of rare and difficult-to-treat diseases and enhance the lives of patients worldwide.

aTyr Pharma SWOT Analysis

Strengths

1. Unique pipeline: aTyr Pharma Inc has a strong portfolio of innovative therapeutics focusing on rare genetic diseases. The company's products have the potential to address unmet medical needs.

2. Patented technology: aTyr's proprietary Physiocrine biology platform enables the discovery and development of protein-based therapeutics. This cutting-edge technology provides the company with a competitive advantage.

3. Strong research and development capabilities: aTyr Pharma has a dedicated team of scientists and experts in biotechnology, ensuring the continuous development of novel drug candidates.

Weaknesses

1. Limited market presence: aTyr Pharma Inc is a relatively small and emerging player in the pharmaceutical industry. This lack of market recognition may pose challenges in gaining widespread adoption of their products.

2. Dependence on key partnerships: The company relies heavily on collaborations with research institutions and pharmaceutical companies for funding and expertise. Any disruption in these partnerships could impact aTyr's operations.

3. High research and development costs: Developing new drugs and conducting clinical trials can be expensive. As a smaller company, aTyr Pharma may face financial constraints in advancing its pipeline at the desired pace.

Opportunities

1. Growing demand for rare disease treatments: The pharmaceutical industry is increasingly focused on developing therapies for rare genetic disorders, presenting aTyr with opportunities to capture a niche market and address significant unmet medical needs.

2. Strategic collaborations: Forming partnerships with larger pharmaceutical companies can provide aTyr with access to additional resources, funding, and expertise necessary for accelerated research and development.

3. Expansion into global markets: As aTyr Pharma's products gain regulatory approvals, there is potential for international expansion, tapping into markets beyond the United States and increasing revenue streams.

Threats

1. Competitive landscape: The pharmaceutical industry is highly competitive, with numerous established players and emerging biotech companies. aTyr Pharma faces the risk of larger competitors developing similar or superior products.

2. Regulatory hurdles: The process of regulatory approvals for drug candidates involves significant time, costs, and uncertainties. aTyr Pharma may face challenges in obtaining necessary approvals, delaying product launches and revenue generation.

3. Economic factors: Global economic fluctuations, healthcare reforms, or changes in reimbursement policies could impact the affordability and accessibility of aTyr's products, affecting market demand.

aTyr Pharma Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

aTyr Pharma Employees
Details
Date
aTyr Pharma Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

aTyr Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

aTyr Pharma historical P/E ratio, EBIT multiple, and P/S ratio

aTyr Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

aTyr Pharma shares outstanding

The number of shares of aTyr Pharma was 98.01 M in 2025. This indicates how many shares aTyr Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
27.79 M Stocks
Jan 1, 2022
29.12 M Stocks
Jan 1, 2023
59.26 M Stocks
Jan 1, 2024
82.72 M Stocks
Jan 1, 2025
98.01 M Stocks
Jan 1, 2026 (e)
98.01 M Stocks
Jan 1, 2027 (e)
98.01 M Stocks
Jan 1, 2028 (e)
98.01 M Stocks

aTyr Pharma stock splits

In aTyr Pharma's history, there have been no stock splits.

Current aTyr Pharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
50.00 % (8)
Hold
50.00 % (8)
Sell
0.00 % (0)
12M Price Target
1.02
Last Price
0.50
Currency
USD
12M Return Potential
102.78 %
LTM Return
0 %

aTyr Pharma Analyst Rating Actions

DateFirmActionRatingReliability
5/20/2026
Freedom Broker
Freedom Broker
UpgradeHoldBuy–
11/7/2025
RBC Capital
RBC Capital
MaintainedSector Perform48
9/16/2025
Wells Fargo
Wells Fargo
DowngradeOverweightEqual Weight53
9/16/2025
RBC Capital
RBC Capital
DowngradeOutperformSector Perform48
9/15/2025
LUCID CAPITAL MARKETS
LUCID CAPITAL MARKETS
DowngradeBuyNeutral–
9/15/2025
Leerink Partners
Leerink Partners
DowngradeOutperformMarket Perform–
9/15/2025
Jones Trading
Jones Trading
DowngradeBuyHold–
9/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
DowngradeBuyNeutral–
9/15/2025
Cantor Fitzgerald
Cantor Fitzgerald
DowngradeOverweightNeutral41
8/22/2025
Jefferies
Jefferies
MaintainedBuy57

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

aTyr Pharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/2026-0.12USD-0.00USD-2026 Q2
5/13/2026-0.15USD-0.00USD-2026 Q1
3/12/2026-0.19USD-29,141.00USD-2025 Q4
8/11/2025-0.19USD-0.00USD-2025 Q2
11/7/2024-0.23USD-20,400.00USD-2024 Q3

aTyr Pharma shareholder structure

% Name
13.62452%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
10.76073%
Federated Hermes Global Investment Management Corp.
Federated Hermes Global Investment Management Corp.
5.45336%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.75053%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.89836%
Octagon Capital Advisors LP
Octagon Capital Advisors LP
2.51131%
Tikvah Management LLC
Tikvah Management LLC
...

aTyr Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
97.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.00%
Logos GP LLC
Logos GP LLC
SEC ↗
11.00%
Logos Global Master Fund LP
Logos Global Master Fund LP
SEC ↗
11.00%
Logos Global Management LP
Logos Global Management LP
SEC ↗
11.00%
Logos Global Management GP LLC
Logos Global Management GP LLC
SEC ↗
11.00%
Arsani William
Arsani William
SEC ↗
11.00%
Timothy P. Lynch
Timothy P. Lynch
SEC ↗
11.00%
Stonepine Capital Management, LLC
Stonepine Capital Management, LLC
SEC ↗
11.00%
Jon M. Plexico
Jon M. Plexico
SEC ↗
11.00%
Laurence W. Lytton
Laurence W. Lytton
SEC ↗
11.00%
Oleg Nodelman
Oleg Nodelman
SEC ↗

aTyr Pharma Executives and Management Board

9 members · avg. age 62 · 56 % women

SS

Dr. Sanjay Shukla (53)

President, Chief Executive Officer, Director · since 2016

1.48 M USD

Management

JB

Ms. Jill Broadfoot (64)

Chief Financial Officer

746,163.00 USD
ND

Ms. Nancy Denyes (57)

General Counsel, Corporate Secretary

729,305.00 USD

Board of Directors

EB

Mr. Eric Benevich (59)

Independent Director

227,301.00 USD
TC

Mr. Timothy Coughlin (58)

Independent Chairman of the Board

129,356.00 USD
JG

Dr. Jane Gross (68)

Independent Director

82,323.00 USD
SL

Dr. Svetlana Lucas (53)

Independent Director

82,264.00 USD
SZ

Dr. Sara Zaknoen (66)

Independent Director

80,263.00 USD
PS

Dr. Paul Schimmel (84)

Independent Director

70,144.00 USD

Frequently asked questions about aTyr Pharma

The business model of aTyr Pharma Inc is focused on discovering and developing first-in-class medicines based on its knowledge of tRNA synthetase biology. By leveraging their expertise in this field, aTyr Pharma aims to harness the potential of these proteins to develop innovative therapies for a range of rare and severe immune and tissue-related diseases. With a dedicated team and a strong pipeline of product candidates, aTyr Pharma is actively working towards addressing unmet medical needs and improving patient outcomes in various therapeutic areas.

aTyr Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of aTyr Pharma Inc in the market include other pharmaceutical companies in the biotechnology industry. Some notable competitors in the field of developing protein therapeutics and novel drugs similar to aTyr Pharma Inc are Genentech, Novartis, Gilead Sciences, and Regeneron Pharmaceuticals. These companies are recognized for their innovations and advancements in the biotech sector, competing with aTyr Pharma Inc by offering alternative treatments and solutions in the market. However, aTyr Pharma Inc distinguishes itself through its unique approach to discovering and developing Physiocrine-based therapeutics for severe rare diseases.

aTyr Pharma Inc is a biotechnology company founded in 2005. Headquartered in San Diego, California, aTyr Pharma is focused on developing innovative therapeutics based on the physiological relevance of tRNA synthetases. The company aims to treat severe rare diseases and immune disorders by targeting these enzymes. With a strong commitment to research and development, aTyr Pharma has made significant advancements in understanding the role of tRNA synthetases in human biology. By leveraging this knowledge, aTyr Pharma aims to provide effective and targeted treatments for patients in need. Through its dedication to scientific innovation, aTyr Pharma Inc has become a leading player in the biotech industry.

aTyr Pharma Inc has achieved several significant milestones throughout its history. One major milestone includes the successful completion of a Phase 1b/2 clinical trial for its lead therapeutic candidate, ATYR1923, in patients with pulmonary sarcoidosis. Additionally, the company has secured partnerships and collaborations with renowned pharmaceutical companies, such as Kyorin Pharmaceutical Co., Ltd. These collaborations have played a crucial role in advancing aTyr Pharma's research and development efforts. Moreover, aTyr Pharma has also received recognition through various industry awards and acknowledgments for its innovative approach to developing novel therapeutics. These milestones highlight aTyr Pharma Inc's continued dedication to advancing and revolutionizing the field of immunology and rare diseases.

aTyr Pharma Inc is primarily present in the United States.

aTyr Pharma Inc represents a strong commitment to innovation, scientific excellence, and improving patient lives. With its corporate philosophy centered around revolutionizing the discovery and development of protein-based therapeutics, aTyr Pharma Inc is dedicated to leveraging its expertise in the field of Physiocrine biology. By focusing on developing potential treatments for rare diseases, this biotechnology company aims to address unmet medical needs and make a meaningful impact in the healthcare industry. aTyr Pharma Inc's emphasis on advanced research and cutting-edge technologies further reinforces its dedication to advancing medicine and enhancing patients' quality of life.

Analysts currently set an average price target of 6.48 USD for the aTyr Pharma stock (median: 1.02 USD), implying +1,189.1 % versus the latest price. The consensus is based on 16 analyst ratings.

aTyr Pharma Analyst Price Targets 2026

16 analysts currently rate the aTyr Pharma stock: 8 recommend buying, 8 holding and 0 selling.

aTyr Pharma Analyst Price Targets 2026

Converted at the current exchange rate, the aTyr Pharma share trades at 0.45 EUR (0.53 USD).

The aTyr Pharma share (ATYR) is listed on 3 stock exchanges, including: NASDAQ (LIFE), Frankfurt (471A.F), München (471A.MU).

aTyr Pharma Inc. is a biopharmaceutical company that focuses on innovative therapeutic approaches for the treatment of rare metabolic and autoimmune diseases. The company is dedicated to developing protein therapeutics derived from natural immunomodulatory proteins and integrates the latest biochemical and physiological findings from academia into its technology platform and preclinical development programs. aTyr Pharma follows a diversified business strategy to develop and bring its product candidates to market. This includes collaborations with other biotech and pharmaceutical companies, as well as the submission of applications for government grants and funding. One of aTyr Pharma Inc.'s main products currently is the drug Resolaris for the treatment of rare muscle diseases such as facioscapulohumeral muscular dystrophy (FSHD). The company is conducting clinical trials to establish Resolaris as an effective and meaningful treatment method in this area. Additionally, aTyr Pharma plans to develop further therapeutics based on its unique protein platform. Another important element of aTyr Pharma Inc.'s business model is close collaboration with key players in the industry, including research institutions and partner companies. The company has already formed several strategic partnerships and collaborations with other biotech and pharmaceutical companies to advance the development and commercialization of its products. These partnerships enable the utilization of existing synergies and help reduce the risk in the development of new products. Furthermore, the company has a clear expansion strategy to extend its therapeutic approaches to new indication areas such as rare metabolic diseases. The existing knowledge and experience in drug development will be utilized to ultimately address market gaps and offer a broader product range. aTyr Pharma pursues a comprehensive research strategy and invests significant resources in researching and developing new approaches for the treatment of rare and severe diseases. Protein-based science has proven to be a relevant platform in recent years, and there is considerable potential in its effective implementation. Overall, aTyr Pharma Inc. has established itself as an innovative biotech company specializing in the development of protein-based therapeutics. The business strategy, the incorporation of partnerships and collaborations, and the emphasis on research and development form the basis for the successful advancement of the company.

The revenue cannot currently be calculated for aTyr Pharma.

The expected profit of aTyr Pharma is -55.25 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of aTyr Pharma is currently -0.94. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the aTyr Pharma stock.

The P/S cannot be calculated for aTyr Pharma currently.

The Eulerpool Quality Score for aTyr Pharma is 2/10.

The ISIN of aTyr Pharma is US0021202025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of aTyr Pharma is A2PM86. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of aTyr Pharma is ATYR. The ticker symbol is used to trade aTyr Pharma shares on the stock exchange.

aTyr Pharma paid dividends every year for the past 0 years.

aTyr Pharma is assigned to the 'Health' sector.

The dividends of aTyr Pharma are distributed in USD.

All fundamentals and in-depth analysis of aTyr Pharma

Our stock analysis for aTyr Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of aTyr Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

aTyr Pharma Stock
aTyr Pharma Revenue→
aTyr Pharma Stock
aTyr Pharma Net Income→
aTyr Pharma Stock
aTyr Pharma P/E→
aTyr Pharma Stock
aTyr Pharma P/S→
aTyr Pharma Stock
aTyr Pharma EBIT→
aTyr Pharma Stock
aTyr Pharma Dividend→
aTyr Pharma Stock
aTyr Pharma Directors Dealings→
aTyr Pharma Stock
aTyr Pharma Stocks→
aTyr Pharma Stock
aTyr Pharma Market capitalization→
aTyr Pharma Stock
aTyr Pharma Debt→
aTyr Pharma Stock
aTyr Pharma Liabilities→
aTyr Pharma Stock
aTyr Pharma Equity→
aTyr Pharma Stock
aTyr Pharma AAQS→
aTyr Pharma Stock
aTyr Pharma Employees→
aTyr Pharma Stock
aTyr Pharma ROE→
aTyr Pharma Stock
aTyr Pharma ROA→
aTyr Pharma Stock
aTyr Pharma ROCE→
aTyr Pharma Stock
aTyr Pharma News→
aTyr Pharma Stock
aTyr Pharma Analyst Price Targets→

Health Stocks

AunaAttendo AB (publ)Aura BiosciencesAtrys HealthAurinia PharmaceuticalsAtrium Therapeutics, Inc. Common StockAurisco Pharmaceutical CoAtriCureAuro LaboratoriesAtossa TherapeuticsAurobindo PharmaAtonAll Stocks A–Z →